INTRODUCTION {#S0001}
============

All genetic variations originate from mutations, which are defined as changes in DNA sequence. Mutations can affect either germline cells (the cells which produce gametes) or somatic cells (all the cells other than germline cells). In human genetics, the term "mutation" has often been reserved for DNA sequence changes that cause genetic diseases and are consequently relatively rare. DNA sequence variants, which are more common in populations (i.e., such sequence variants in which two or more alleles at locus demonstrate frequencies \>1%), are said to be polymorphic ("having many forms") \[[@CIT0001]\]. Such loci (plural of locus) are termed polymorphisms, although nowadays, alleles with frequency \<1% are often called polymorphisms as well.

Urinary bladder cancer is a common malignant disease in Poland \[[@CIT0002]\]. Many genetic and epigenetic alterations are supposed to contribute directly or indirectly to bladder tumor induction \[[@CIT0003], [@CIT0004]\]. Attempts are undertaken to classify tumors with regards to the molecular characteristics of changes in neoplastic cells in order to be able to identify the relationship between the type of these changes and clinical characteristics. Every type of cancer has biological subsets that differ in clinical behavior and response to treatment. Personalized cancer medicine is defined as treatment based on the molecular characteristics of a tumor from individual patient. Nowadays this branch of medicine has great potential in the therapy of many types of cancer. Somatic mutations of *P53, Rb, FGFR3, CDKN2A*, and *Ras* genes belong to the group of mutations that most frequently accompany the occurrence of urinary bladder carcinoma \[[@CIT0003], [@CIT0004], [@CIT0005]\]. Some of the constitutive changes of the genes (germline), e.g., A72P polymorphism of *P53* gene, were also analyzed with regards to the higher risk of neoplasm development \[[@CIT0006]\]. There are also reports, indicating correlations between constitutive mutations of *CDKN2A* gene and breast cancer, melanoma cancer, nervous system tumours and squamous cell carcinoma of the head/neck region \[[@CIT0007], [@CIT0008], [@CIT0009]\], but rather little is known either about the frequency of its occurrence or of its significance in urinary bladder carcinoma. Most frequently described polymorphisms of *CDKN2A* gene are the substitution of alanine to threonine in the second exon (A148T- rs 3731249) and the two, which occur in the 3′ untranslated region of *CDKN2A:* NT 500c \>g and Nt540c \>t \[[@CIT0007]\].

The *CDKN2A* gene (OMIM 600160), localized at chromosome 9p21 encodes p16I^NK4a^ cyclin-dependent kinase inhibitor and p14AR activator of p53 \[[@CIT0003]\]. Both gene products have an independent first exon (1-alpha exon and 1-beta exon, respectively), but share exons 2 and 3 and are translated in different reading frames. The genes are involved in the negative control of cell proliferation; p16^INK4a^ produces a G1 cell-cycle arrest by inhibiting the phosphorylation process of retinoblastoma protein (RB), and p14^ARF^ acts both at G1/S phases in a p53-dependent manner via binding and inhibiting MDM2 protein. There are three major mechanisms at the base of genetic inactivation of *CDKN2A* gene, including deletions of both alleles, deletion of one allele and mutation of the other allele or deletion or mutation of the first allele and hypermethylation of the second allele. Unlike other suppressor genes, which most often undergo inactivation in result of point mutations, deletions are the most frequent mechanisms by which *CDKN2A* gene is inactivated. Regarding urinary bladder carcinoma, homozygotic deletions at 9p21 locus *(CDKN2A)* are found in approximately 20-30% of cases, while the loss of heterozygosity may be observed even in 60% of cases \[[@CIT0003], [@CIT0008]\].

The aim of our study was to characterize A148T polymorphism of *CDKN2A* gene in bladder cancer patients.

MATERIAL AND METHODS {#S0002}
====================

DNA from 84 subjects was analyzed, all of them patients of the Department of Urology, The J.P. II Regional Hospital in Bełchatów, and from 72 patients of the "Urologists M. Rozniecki and Partners" Department of Urology in Łask with diagnosed tumor of the urinary bladder (130 men and 26 women, 32-86 year old, the mean age: 62.3 years).

The patients were informed about the study goal and provided written consents to participate. A detailed medical history was obtained from all the enrolled participants, taking into account the effect of risk factors on neoplastic disease progression. All the identified neoplasms were assessed by two histopathologists for staging and grading according to WHO Histopathological Classification \[[@CIT0010]\]. The mean observation period per individual patient was 32 months (16-59). The number of recurrence cases amounted to 59/156 (38%).

See [Tables 1](#T0001){ref-type="table"} and [2](#T0002){ref-type="table"} for data of the analyzed material.

###### 

Clinical data of the bladder cancer group (the dark blue color designates the cases in which A148T polymorphism of CDKN2A gene was found)

  No.   DNA    Gender/Age   Stage/Grade   Recurrence (time after diagnosis in months)   No.   DNA   Gender/ Age   Stage/ Grade   Recurrence
  ----- ------ ------------ ------------- --------------------------------------------- ----- ----- ------------- -------------- ------------
  1     151    M/44         Ta/G1         Yes/18                                        81    141   M/56          T1/G2          No
  2     166    M/66         Ta/G1         Yes/5,12                                      82    153   M/43          /T1G2          No
  3     168    M/51         Ta/G1         No                                            83    154   M/81          T1/G2          Yes
  4     169    M/47         Ta/G1         Yes/8,18                                      84    162   M/73          T1/G2          Yes
  5     171    M/65         Ta/G1         No                                            85    L1    M/62          T1/G3          No
  6     175    M/32         Ta/G1         No                                            86    L2    M/82          Ta/G2          No
  7     178    M/66         Ta/G1         No                                            87    L3    M/57          T1/G2          Yes/1
  8     182    M/84         Ta/G1         No                                            88    L4    M/53          Ta/G1          Yes/1
  9     187    M/82         Ta/G1         No                                            89    L5    M/77          T1/G2          Yes/3
  10    188    M/54         Ta/G1         Yes/16                                        90    L6    M/62          Ta/G2          Yes/6
  11    189    M/63         Ta/G1         Yes/17,19                                     91    L7    F/59          Ta/G1          No
  12    190    M/70         Ta/G1         Yes/11                                        92    L8    M/73          T3/G2          No
  13    192    M/67         Ta/G1         No                                            93    L9    M/78          Ta/G1          No
  14    193    M/83         Ta/G1         No/D                                          94    L10   F/68          T1/G2          Yes/1
  15    195    M/60         Ta/G1         Yes/9,17                                      95    L11   M/61          T1/G2          No
  16    196    M/77         Ta/G1         No                                            96    L12   M/60          Ta/G1          No
  17    197    M/76         Ta/G1         No                                            97    L13   M/41          Ta/G1          Yes/4
  18    198    M/53         Ta/G1         Yes/3                                         98    L14   M/59          Ta/G1          No
  19    203    M/61         Ta/G1         No                                            99    L15   M/77          Ta/G2          No
  20    204    M/75         Ta/G1         Yes/15                                        100   L16   F/82          Ta/G1          No
  21    206    M/71         Ta/G1         No                                            101   L17   M/85          Ta/G3          No
  22    209    M/58         Ta/G1         No                                            102   L18   M/68          T1/G3          Yes/3
  23    210    M/58         Ta/G1         Yes/4                                         103   L19   M/57          Ta/G1          Yes/7
  24    211    M/54         Ta/G1         No                                            104   L20   F/61          T1/G1          No
  25    219    M/55         Ta/G1         No                                            105   L21   F/83          Ta/G1          No
  26    220    M/67         Ta/G1         No                                            106   L22   M/62          T2/G2          Yes/3
  27    221    F/53         Ta/G1         No                                            107   L23   M/41          Ta/G1          Yes
  28    226    M/52         Ta/G1         No                                            108   L24   M/63          Ta/G2          Yes/3
  29    228    M/67         Ta/G1         No                                            109   L25   M/67          Ta/G3          Yes
  30    234    M/67         Ta/G1         No                                            110   L26   F/57          Ta/G1          No
  31    238    M/73         Ta/G1         No                                            111   L27   M/53          T1/G2          No
  32    235    M/52         Ta/G1         No                                            112   L28   M/73          T1/G3          Yes
  33    240    M/83         Ta/G1         No                                            113   L29   F/54          T1/G2          No
  34    241    M/78         Ta/G1         Yes/12                                        114   L30   F/50          Ta/G1          No
  35    242    M/61         Ta/G1         No                                            115   L31   M/61          Ta/G1          Yes/2
  36    247    M/59         Ta/G1         Yes/6                                         116   L32   F/44          Ta/G1          No
  37    249    M/61         Ta/G1         No                                            117   L33   M/81          Ta/G1          No
  38    251    F/73         Ta/G1         Yes/3,9                                       118   L34   M/66          Ta/G2          Yes/6
  39    255    M/56         Ta/G1         No                                            119   L35   M/67          Ta/G1          Yes/24
  40    165    M/55         Ta/G2         Yes/5,9,14/D                                  120   L36   M/52          T1/G2          Yes/9
  41    170    M/74         Ta/G2         No                                            121   L37   M/79          Ta/G1          No
  42    184    M/60         Ta/G2         Yes/1                                         122   L38   M/62          Ta/G1          Yes/3
  43    232    M/73         Ta/G2         No                                            123   L39   M/67          T1/G3          Yes/12
  44    245    M/73         Ta/G2         Yes/5                                         124   L40   M/70          Ta/G1          Yes/3
  45    212    M/80         T1/G1         No                                            125   L41   M/74          Ta/G1          Yes/1
  46    214    F/45         T1/G1         No                                            126   L42   M/58          Ta/G1          Yes/3
  47    222    M/71         T1/G1         No/Dacc                                       127   L43   F/69          Ta/G1          Yes/2
  48    223    M/70         T1/G1         No/Dint                                       128   L44   M/68          Ta/G1          Yes/2
  49    244    M/77         T1/G1         No                                            129   L45   M/62          Ta/G1          Yes/3
  50    248    M/62         T1/G1         No/Dint                                       130   L46   M/72          Ta/G1          Yes/3
  51    173    M/86         T1/G2         No                                            131   L47   M/54          Ta/G2          Yes/3
  52    179    M/84         T1/G2         Yes/20                                        132   L48   F/62          T1/G1          No
  53    202    M/71         T1/G2         Yes                                           133   L49   F/60          Ta/G1          Yes/3
  54    218    M/72         T1/G2         Yes/4/D                                       134   L51   F/58          Ta/G1          No
  55    227    M/80         T1/G2         No/D                                          135   L52   F/78          Ta/G1          Yes/1
  56    231    M/57         T1/G2         No                                            136   L53   F/77          T1/G3          No
  62    237    M/60         T1/G2         Yes/3/D                                       137   L54   M/67          T1/G3          Yes/3
  57    252    M/83         T1/G2         No                                            138   L56   F/75          T1/G1          No
  58    205    M/53         T1/G3         No                                            139   L57   M/58          T1/G1          No
  59    215    M/84         T1/G3         Yes/6/D                                       140   L58   M/64          T1/G1          No
  60    243    M/72         T1/G3         No/D                                          141   P2    M/66          Ta/G2          No
  61    256    M/68         T1/G3         No                                            142   P3    F/76          Tis/G3         No
  62    217    M/83         T2/G1         Yes/1/D                                       143   P4    M/75          T1/G1          Yes
  63    185    K/76         T2/G2         No/D                                          144   P5    F/57          T1/G2          Yes
  64    191    M/82         T2/G2         No/D                                          145   P6    M/72          T2/G2          No
  65    199    M/82         T2/G2         No/D                                          146   P7    M/64          T2/G3          No
  66    200    M/55         T2/G2         No/D                                          147   P8    M/72          T2/G3          No
  67    208a   F/78         T2/G2         No/D                                          148   P9    M/76          T1/G1          No
  68    177    M/65         T2/G3         No/D                                          149   P11   M/49          T2/G3          No
  69    180    M/76         T2/G3         No/D                                          150   P13   F/45          T1/G1          No
  70    183    F/61         T2/G3         Yes/12                                        151   P20   M/54          T1/G1          Yes
  71    201    M/74         T2/G3         No/D                                          152   P23   M/66          T2/G3          Yes
  72    186    M/67         T2/G3         No                                            153   P24   M/76          T1/G1          Yes
  73    213    M/77         T2/G3         No                                            154   P25   M/72          T2/G2          Yes
  74    230    F/88         T2/G3         No/D                                          155   P26   M/65          T2/G3          Yes
  75    239    F/62         T2/G3         No                                            156   P28   F/61          T2/G2          Yes
  76    253    M/73         T2/G3         No                                                                                     
  77    254    M/72         T2/G3         No                                                                                     
  78    208    F/75         T3/G3         No/D                                                                                   
  80    207    M/81         T4/G3         No                                                                                     

D - death, Dacc - death in accident, Dint - death of intrinsic cause

###### 

Division of studied material with regards to tumor staging and grading

  Tumor stage   Tumor grade                               
  ------------- ------------- -------- -------- --------- --------
  **Tis**       1                                         
  **Ta**        53            28       **G1**   61        23
  **T1**        33            9        **G2**   28        14
  **T2**        18            7        **G3**   23        7
  **T3-T4**     7                                         
  **Total**     **112**       **44**            **112**   **44**

DNA isolation {#S20003}
-------------

Blood samples (5 ml), collected onto EDTA~3~K (potassium versenate), were used as study material. A Roche MagNA Pure Compact automatic workstation was used to isolate DNA from 1 ml of anticoagulated blood (out of all samples) by means of a Nucleic Acid Isolation Kit I-Large Volume (cat. No. 03 730 972 001, Roche Diagnostic GmbH). The volume and purity of obtained DNA were determined by absorbance (A) measurements directly in aqueous solutions. The measurements were performed by an ND-1000 spectrophotometer in UV light (measurement of UV adsorbed by DNA bases). Nucleic acid concentration was determined by comparing measurement results for blind trial (distilled water) and absorbance levels of studied sample at wavelength of 260 nm (this wave length corresponds to the maximal absorption for nucleic acids). Purity was determined by calculation of A~280~/A~260~ coefficient. Absorbance at λ = 280 nm is characteristic for proteins and reflects protein- derived contaminations. The coefficient values above 1.7 were regarded satisfactory.

PCR conditions {#S20004}
--------------

PCR amplifications were performed as follows: 1 μl of template DNA (approx. 100 ng), 2.5 μl of 10 × reaction buffer (700 mM Tris-HCl, pH 8.3, 166 mM (NH~4~)~2~SO~4~, 25 mM MgCl~2~), 0.5 μl of 2,5 mM dNTPs (TaKaRa), 1 μl of each primer pair (5 pmol/ μl), 1.25 U of *Taq* DNA polymerase (Novazym), and 18.75 μl of distilled water in a total volume of 25 μl were used. The used primers included: 5′CCCAAGCTTGCATGGAGCCGGCGGCG3′ and 5′CGGGATCCCTTTCAATCGGGGATGT3′. The applied PCR procedure: preliminary denaturation for 10 minutes at 95°C, followed by 40 cycles of 30-second denaturation in 95°C, 30-second annealing in 58°C, and 30-second elongation in 72°C. The final elongation lasted 5 minutes at 72°C. All the reactions were referred to non-template controls. PCR reactions were carried out on BioRad iQ5 and LabCycler SensoQuest thermocyclers. PCR products of leukocytes (10 μl) were electrophoresed on 2.0% agarose gel and stained with ethidium bromide. The gels were evaluated by visual inspection in UV light.

MSSCP (Multitemperature Single Strand Conformation Polymorphism) conditions {#S20005}
---------------------------------------------------------------------------

The search for A148T polymorphism in exon 2 of *CDKN2A* gene was carried out by the MSSCP technique in two different temperature profiles (the first one at 23°C, for 120 minutes and the second one at 37°C for 40 minutes, 23°C for 25 minutes, and at 15°C for 25 minutes) and by the sequencing technique. Details of the MSSCP method were described in earlier reports \[[@CIT0011]\]. PCR products were sequenced to rule out / confirm mutation or polymorphism, identified during electrophoresis (Genomed sp. z o.o.).

Statistics {#S20006}
----------

The G test, based on the likelihood ratio, was applied. Like the chi-square (χ^2^) test, G test is used to assess the significance of differences in contingency tables. Both tests lead to the same conclusions when each cell of the contingency table has a sufficiently high number (O \>10) of observations. However, while the chi-square test cannot be used for lower numbers in any cell, no such restrictions occur for G test. A null hypothesis of no effect cannot be rejected when G statistics is higher than the critical value G~0,05~ = 3.841 for 1 degree of freedom (table 2×2) \[[@CIT0012]\].

RESULTS {#S0007}
=======

Common polymorphic variants of *CDKN2A* gene were found in our study at codon 148 in exon 2 (Ala148Thr) in 9 cases ([Tab. 3](#T0003){ref-type="table"}, [Fig. 1](#F0001){ref-type="fig"}). All the confirmed cases were first identified by the MSSCP technique and then verified by sequencing. A full conformability of results was attained in both techniques. The obtained frequencies were compared with the control group from the Polish population, examined by Debniak and colleagues, and a significant difference was found in the prevalence of A148T polymorphism in the bladder cancer group (G test, Table 2 ×2: N~BLADDER\ CANCER~ = 156, N~CONTROL~ = 1210, G = 4.298, p \<0.05) \[[@CIT0013]\]. No differences were observed in the frequencies of Nt500c \>g alleles or in the frequencies of Nt540c \>t alleles, either in the bladder cancer group or in the reference control group. We used the data for the control group, published by other authors, because they were obtained in studies on a large number of subjects (i.e., 1210) for the Polish population, and by researchers, who are unquestionable authorities in the studies on hereditary predispositions to neoplasm development, including the A148T variant of *CDKN2A* gene.

###### 

Frequencies of *CDKN2A* variants in controls and in the bladder cancer group

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  CDKN2A   Debniak et.al (n=1210) controls                                      This study (n=156)                                                     G test (table 2×2)
  -------- -------------------------------------------------------------------- ---------------------------------------------------------------------- --------------------
  A148T    A/A 0 (0%) A/G 35 (2.89%) G/G 1175 (97.1%) Allele A frequency 1.5%   A/A 1 (0.64%) A/G 8 (5.13%) G/G 147 (94.23%) Allele A frequency 3.2%   G= 4.298\
                                                                                                                                                       p\<0.05

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------

![Results of electrophoresis (MSSCP) of *CDKN2A* gene exon 2 and of sequentioning of particular codon 148 variants. The black arrow designates the G/G (Ala/Ala) homozygotic system, the blue arrow -- the heterozygotic A/G (Thr/Ala) system and the red arrow -- the homozygotic A/A (Thr/Thr) system.](CEJU-64-00102-g001){#F0001}

![The incidence rates of particular variants in codon 148 of *CDKN2A* gene in various neoplasms, found in the Polish population. The occurrence of adenine instead of guanine in codon 148 is associated with the change of the coded amino acid - alanine (CGG) - to threonine (CGA).\
n- the number of studied subjects controls - a control group for the Polish population, consisting of 500 newborns and 710 adult; „significant" - designates a group of neoplasms, in which the percent of the threonine-encoding variant was statistically significantly higher than in the control population; „not significant" - designates a group of neoplasms in which the distribution of incidence of the threonine-encoding variant is not different from that in the general population.\
Based on the study by Dębniak et al. 2006 \[[@CIT0031]\].](CEJU-64-00102-g002){#F0002}

DISCUSSION {#S0008}
==========

*CDKN2A* gene inactivation is one of the genetic events, leading to urinary bladder cancer development \[[@CIT0003]\]. According to published reports, 14-39% of homozygotic deletions are found in urinary bladder cancer, as well as approximately 12% of hemizygotic deletions of the gene and about 3% of mutations \[[@CIT0005], [@CIT0014]\]. For comparison, in renal cancer homozygotic deletions are observed even in 56%, while hypermethylation in 23% of the diagnosed cases \[[@CIT0015]\]. However, because *CDKN2A* gene inactivation plays the key role in the molecular mechanism of urinary bladder cancer development, as designed by Goebell et al. in 2010, our interest focused on the constitutional mutations of that gene.

The A148T variant is broadly cited as a common polymorphism, following functional studies, which indicate that these amino acid substitutions do not affect the ability of P16 to precipitate with CDK4/ CDK6 proteins \[[@CIT0013]\]. Variable frequencies of *CDKN2A* germline muta tions and polymorphism have been reported in different collections of melanoma families in Sweden, Poland, Great Britain, and Brazil \[[@CIT0016]--[@CIT0020]\]. The incidence rates of these changes are also higher in cases of liver carcinoma, nervous system tumors, and pancreatic or breast cancers. See [Table 5](#T0005){ref-type="table"} for exemplary data.

In Poland, the incidence of *CDKN2A* variant - an alanine to threonine substitution at codon 148 (A148T) - has been estimated for approximately 3 to 3.5% of the population \[[@CIT0013], [@CIT0021]\]. Recent studies have shown that A148T polymorphism is in linkage disequilibrium with a second alteration in the *CDKN2A* promoter (P-493 variant), which appears to affect gene expression \[[@CIT0013]\]. In the Polish control population, the frequency of A148T changes in 1,210 control samples (500 newborns and 710 adults) was assessed by Debniak et al. at 2.89%. The same research team studied the incidence of A148T variant of *CDKN2A* gene (see their report of 2007) in the Polish population of patients with breast cancer (young women), colon, lung, melanoma, prostate, bladder, kidney, stomach, pancreas and thyroid cancers (see [Figure 1](#F0001){ref-type="fig"} for a partial presentation of results) \[[@CIT0013], [@CIT0030], [@CIT0031]\]. Significant differences were found for the first four neoplasms in the above list, indicating that the carrier state of the variant may be associated with an increased risk of tumor development. The results, obtained for a group of 223 urinary bladder carcinoma cases (3.1%) did not differ from those for the control group \[[@CIT0013]\]. It should be emphasized that those patients came from the Pomeranian Region while in our study patients from the Lodz Voivodeship (central Poland) prevailed (131/156). The results of our study (5.77%) indicate that, regarding the Polish population (Łódź Macroregion), A148T variant seems to be associated with an increased bladder cancer risk. However, it should eventually be justified to refer to the comparison of results in the study group with those in the control group, representative for the studied region. The frequency of variant A148T found by us in patients with bladder cancer is similar to the results published in the work of Sakano et al. (6%) for patients with bladder cancer in the population of Stockholm county in Sweden \[[@CIT0029]\]. However, the result cannot be compared with a general population as the authors do not specify what is the frequency of this variant in the population of Swedes.

The obtained results should by all means be confirmed in a study on a larger population, representing the Łódź Macroregion, especially that the results of studies on other neoplasms differ among populations or even within the same population, when differentiated for example by age (the groups of patients below and above the age of 50 years). Breast cancer can be an example, the results for which were different from those in the control group in the group of women below 50, while no differences in the incidence rates were observed between the control group and the group of women above 50 \[[@CIT0031]\]. In case of the studied group, 8 out of 9 A148T polymorphism cases of *CDKN2A* gene were identified in men at the age above 60 years at diagnosis (data specified in [Table 4](#T0004){ref-type="table"}). No recurrence was observed in 7 out of 9 diagnosed cases. In 6/9 cases, there were neoplasms in high clinical stage; while in 5/9 cases there were tumors with high malignancy grade (G2-G3). Summing up and taking into account the analysis of clinical parameters and the age of disease occurrence, A148T polymorphism of *CDKN2A* gene was found in the studied group only in men, in whom the disease was diagnosed at the age above 60 years, while the diagnosed neoplasms were in the majority of cases characterized by higher clinical stage and higher grade of malignancy, as well as by a low percentage of recurrence. Nevertheless, this has been the first study that attempted to show a potential association between A148T alterations and an increased risk for bladder cancer development.

###### 

Prevalence of A148T variant of *CDKN2a* gene vs. clinical data

                      N (%)        A148T (+) N (%)
  ------------------- ------------ -----------------
  Sex:                             
  Male                130 (83.3)   9 (6.9)
  Female              26 (16.7)    0 (0.0)
  Age:                             
  ≤60                 45 (28.8)    1 (2.2)
  ≥61                 111 (71.2)   8 (8.1)
  Grade:                           
  I                   84 (53.8)    4 (4.8)
  ≥II                 72 (46.2)    5 (6.9)
  Stage:                           
  Ta                  81 (51.9)    3 (3.7)
  ≤T1                 75 (48.1)    6 (8.0)
  Local recurrence:                
  Positive            59 (37.8)    2 (3.3)
  Negative            97 (62.2)    7 (7.2)

###### 

Genotypes and allele frequencies of the A148T allele in different populations

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
        Geographic origin               Study population                                                  Genotype   Frequency of A148T gene CDKN2A polymorphism   Reference
  ----- ------------------------------- ----------------------------------------------------------------- ---------- --------------------------------------------- ----------------------------------------
  1\.   North-Western Italy             Melanoma families n = 14                                          --         5/14 (35.7%)                                  Chiorzo et al. (1999) \[[@CIT0022]\]

  2\.   French and Italian population   Italian melanoma patients n = 119\                                \          6.72%\                                        Spica et al. (2006) \[[@CIT0024]\]
                                        \                                                                 A/A\       1 (0.84%)\                                    
                                        \                                                                 G/A\       14 (11.76%)\                                  
                                        \                                                                 G/G\       104 (87.40%)\                                 
                                        \                                                                 \          \                                             
                                        Italian controls n = 121\                                         \          6.2%\                                         
                                        \                                                                 A/A\       1 (0.83%)\                                    
                                        \                                                                 G/A\       13(10.74%)\                                   
                                        \                                                                 G/G\       107 (88.43%)\                                 
                                        \                                                                 \          \                                             
                                        French melanoma patients n = 500\                                 \          3.4%\                                         
                                        \                                                                 A/A\       1 (0.2%)\                                     
                                        \                                                                 G/A\       32 (6.4%)\                                    
                                        \                                                                 G/G\       467 (93.4%)\                                  
                                        \                                                                 \          \                                             
                                        French controls n = 143                                           \          4.2%\                                         
                                                                                                          A/A\       0 (0.0%)\                                     
                                                                                                          G/A\       12 (8.4%)\                                    
                                                                                                          G/G        131 (91.6%)                                   

  3\.   UK                              Atypical nevus/Familial melanoma n = 488\                         A/A\       0/488 (0.0%)\                                 Bertram et al. (2002) \[[@CIT0023]\]
                                        \                                                                 G/A\       24/488 (4.9%)\                                
                                        \                                                                 G/G\       464/488 (93.0%)\                              
                                        Population-based sample n = 599                                   \          \                                             
                                                                                                          \          \                                             
                                                                                                          A/A\       0/599 (0.0%)\                                 
                                                                                                          G/A\       31/599 (5.2%)\                                
                                                                                                          G/G        568/599 (94.8%)                               

  4\.   Sweden                          Hereditary melanoma n = 108                                       --         9.3% in patients sample                       Erlandson et al. (2007) \[[@CIT0025]\]

  5\.   Spain                           Patients with more than one primary cutaneous melanoma n = 104\   --         13.40%\                                       Puig et al. (2005) \[[@CIT0026]\]
                                        Spanish controls n = 110                                                     5.45%                                         

  6\.   Spain                           Breast cancer and cutaneous melanoma n = 31                       --         2/31 (6.4%)                                   Nagore et al. (2009) \[[@CIT0027]\]

  7\.   Poland                          Larynx cancer n = 390                                             --         17/390 (4.4%)                                 Kiwerska et al. (2007) \[[@CIT0028]\]

  8\.   Sweden (Stockholm County)       Bladder cancer n = 167                                            --         10/167 (6%)                                   Sakano et al. (2003) \[[@CIT0029]\]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CONCLUSION {#S0009}
==========

Studies on genetic predispositions to neoplasm development allow to distinguish the group of subjects with an increased risk for neoplastic changes vs. the general population. The more we learn about human genetics and human variations, the more apparent it becomes that our individual make-up has a noticeable impact on the risk of cancer development and finally on the effectiveness of therapeutic medications. A148T variant of *CDKN2A* gene seems to be associated with an increased risk for developing bladder cancer. Nevertheless, according to Debniak et al. (2005), it does not imply that A148T polymorphism is associated with an increased risk of the diseases alone but it rather suggests the existence of some interactive modifiers that, when grouped together, may trigger the malignancy process.
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